Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model

Larissa Lachi-Silva; Sherwin K. B. Sy; Alexander Voelkner; João Paulo Barreto de Sousa; João Luis C. Lopes; Denise B. Silva; Norberto P. Lopes; Elza Kimura; Hartmut Derendorf; Andrea Diniz

doi:10.1055/s-0035-1546214

Planta Medica, Table of Contents

Planta Med 2015; 81(12/13): 1121-1127
DOI: 10.1055/s-0035-1546214

Pharmacokinetic Investigations

Original Papers

Georg Thieme Verlag KG Stuttgart · New York

Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model^[*]

Authors

Larissa Lachi-Silva

¹Preclinical Pharmacokinetic Laboratory, Department of Pharmacy, Maringa State University, Maringa, PR, Brazil
Sherwin K. B. Sy

²Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA

³Biostatistics Master Program, Department of Statistics, Maringa State University, Maringa, PR, Brazil
Alexander Voelkner

²Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
João Paulo Barreto de Sousa

⁴NPPNS (Núcleo de Pesquisa em Produtos Naturais e Sintéticos), Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
João Luis C. Lopes

⁴NPPNS (Núcleo de Pesquisa em Produtos Naturais e Sintéticos), Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
Denise B. Silva

⁴NPPNS (Núcleo de Pesquisa em Produtos Naturais e Sintéticos), Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil

⁵LAPNEM (Laboratório de Produtos Naturais e Espectrometria de Massas), Centro de Ciências Biológicas e da Saúde (CCBS), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, MS, Brazil
Norberto P. Lopes

⁴NPPNS (Núcleo de Pesquisa em Produtos Naturais e Sintéticos), Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
Elza Kimura

¹Preclinical Pharmacokinetic Laboratory, Department of Pharmacy, Maringa State University, Maringa, PR, Brazil
Hartmut Derendorf

²Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
Andrea Diniz

¹Preclinical Pharmacokinetic Laboratory, Department of Pharmacy, Maringa State University, Maringa, PR, Brazil

Abstract

The pharmacokinetic properties of a new molecular entity are important aspects in evaluating the viability of the compound as a pharmacological agent. The sesquiterpene lactone lychnopholide exhibits important biological activities. The objective of this study was to characterize the pharmacokinetics of lychnopholide after intravenous administration of 1.65 mg/kg (n = 5) and oral administration of 3.3 mg/kg (n = 3) lychnopholide in rats (0.2 ± 0.02 kg in weight) through nonlinear mixed effects modeling and non-compartmental pharmacokinetic analysis. A highly sensitive analytical method was used to quantify the plasma lychnopholide concentrations in rats. Plasma protein binding of this compound was over 99 % as determined by a filtration method. A two-compartment body model plus three transit compartments to characterize the absorption process best described the disposition of lychnopholide after both routes of administration. The oral bioavailability was approximately 68 %. The clearance was 0.131 l/min and intercompartmental clearance was 0.171 l/min; steady-state volume of distribution was 4.83 l. The mean transit time for the absorption process was 9.15 minutes. No flip-flop phenomenon was observed after oral administration. The pharmacokinetic properties are favorable for further development of lychnopholide as a potential oral pharmacological agent.

Key words

lychnopholide - pharmacokinetic - transit compartment - model-based development - pharmacognosy - population pharmacokinetic

Full Text

References

References
1 Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311-335
2 Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Discov Devel 2009; 12: 189-196
3 Krause J, Tobin G. Discovery, development and regulation of natural products. In: Marianna K, editor Using old solutions to new problems – natural drug discovery in the 21st century. Rijeka, Croatia: InTech; 2013: 3-36
4 Szychowski J, Truchon JF, Bennani YL. Natural products in medicine: transformational outcome of synthetic chemistry. J Med Chem 2014; 57: 9292-9308
5 Galvanin F, Ballan CC, Barolo M, Bezzo F. A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models. J Pharmacokinet Pharmacodyn 2013; 40: 451-467
6 Brantley SJ, Gufford BT, Dua R, Fediuk DJ, Graf TN, Scarlett YV, Frederick KS, Fisher MB, Oberlies NH, Paine MF. Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction. CPT Pharmacometrics Syst Pharmacol 2014; 3: e107
7 Sy SK, Wang X, Derendorf H. Introduction to pharmacometrics and quantitative pharmacology with an emphasis on physiologically based pharmacokinetics. In: Schmidt S, Derendorf H, editors Applied pharmacometrics. New York: Springer; 2014: 1-64
8 Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R. Model-based drug development. Clin Pharmacol Ther 2007; 82: 21-32
9 Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, Nucci G, Nichols DJ, Boyd RA, Mandema JW, Krishnaswami S, Zwillich S, Gruben D, Anziano RJ, Stock TC, Lalonde RL. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther 2013; 93: 502-514
10 Miller R, Ewy W, Corrigan BW, Ouellet D, Hermann D, Kowalski KG, Lockwood P, Koup JR, Donevan S, El-Kattan A, Li CS, Werth JL, Feltner DE, Lalonde RL. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005; 32: 185-197
11 Chadwick M, Trewin H, Gawthrop F, Wagstaff C. Sesquiterpenoids lactones: benefits to plants and people. Int J Mol Sci 2013; 14: 12780-12805
12 Barrero A, Oltra J, Justícia J, Raslan D, Silva E. Atividade antibacteriana de furanoeliangólidos/Antibacterial activity of furanoeliangolides. Rev Bras Farmacogn 2002; 12: 7-10
13 Saúde-Guimarães DA, Faria AR. Substâncias da natureza com atividade anti-Trypanosoma cruzi . Rev Bras Farmacogn 2007; 17: 455-465
14 Ferrari FC, Ferreira LC, Souza MR, Grabe-Guimaraes A, Paula CA, Rezende SA, Saude-Guimaraes DA. Anti-inflammatory sesquiterpene lactones from Lychnophora trichocarpha Spreng. (Brazilian Arnica). Phytother Res 2013; 27: 384-389
15 Raslan D, Oliveira A. In vitro antitumor activity of sesquiterpene lactones from Lychnophora trichocarpha . Revista Bras Plant Med 2014; 16: 275-282
16 Ren Y, Acuna UM, Jimenez F, Garcia R, Mejia M, Chai H, Gallucci JC, Farnsworth NR, Soejarto DD, Carcache de Blanco EJ, Kinghorn AD. Cytotoxic and NF-kappaB inhibitory sesquiterpene lactones from Piptocoma rufescens . Tetrahedron 2012; 68: 2671-2678
17 Schmidt TJ. Toxic activities of sesquiterpene lactones: structural and biochemical aspects. Curr Org Chem 1999; 3: 4
18 Schmidt TJ, Khalid SA, Romanha AJ, Alves TM, Biavatti MW, Brun R, Da Costa FB, de Castro SL, Ferreira VF, de Lacerda MV, Lago JH, Leon LL, Lopes NP, das Neves Amorim RC, Niehues M, Ogungbe IV, Pohlit AM, Scotti MT, Setzer WN, de N C Soeiro M, Steindel M, Tempone AG. The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases – part II. Curr Med Chem 2012; 19: 2176-2228
19 Jabor VA, dos Santos MD, Bonato PS, Gouvea DR, Lopes NP. A new high-performance liquid chromatography assay for the determination of sesquiterpene lactone 15-deoxygoyazensolide in rat plasma. Anal Chim Acta 2007; 601: 212-217
20 Canalle R, Burim RV, Callegari Lopes JL, Takahashi CS. Assessment of the cytotoxic and clastogenic activities of the sesquiterpene lactone lynchnopholide in mammalian cells in vitro and in vivo . Cancer Detect Prev 2001; 25: 93-101
21 Branquinho RT, Mosqueira VC, de Oliveira-Silva JC, Simoes-Silva MR, Saude-Guimaraes DA, de Lana M. Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas disease. Antimicrob Agents Chemother 2014; 58: 2067-2075
22 Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in drug-resistant pulmonary tuberculosis patients. Antimicrob Agents Chemother advance online publication 2015 May 11; DOI:
23 de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 2014; 58: 6242-6250
24 Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007; 34: 711-726
25 Shilbayeh SA, Sy SK, Melhem M, Zmeili R, Derendorf H. Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. Clin Pharmacol Drug Devel advance online publication 12 January 2015; DOI:
26 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095
27 Xing J, Yan H, Zhang S, Ren G, Gao Y. A high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemisinin in rat plasma. Rapid Commun Mass Spectrom 2006; 20: 1463-1468
28 Guo C, Zhang S, Teng S, Niu K. Simultaneous determination of sesquiterpene lactones isoalantolactone and alantolactone isomers in rat plasma by liquid chromatography with tandem mass spectrometry: application to a pharmacokinetic study. J Sep Sci 2014; 37: 950-956
29 Exposure Assessment Tools and Models. Estimation program interface suite (EPI Suite) version 4.11. Washington, DC: US Environmental Protection Agency; 2012. Software available at http://www.epa.gov/opptintr/exposure/pubs/episuitedl.htm
30 Branquinho RT, Mosqueira VC, Kano EK, de Souza J, Dorim DD, Saude-Guimaraes DA, de Lana M. HPLC-DAD and UV-spectrophotometry for the determination of lychnopholide in nanocapsule dosage form: validation and application to release kinetic study. J Chromatogr Sci 2014; 52: 19-26
31 Wagner S, Kratz F, Merfort I. In vitro behaviour of sesquiterpene lactones and sesquiterpene lactone-containing plant preparations in human blood, plasma and human serum albumin solutions. Planta Med 2004; 70: 227-233
32 Diniz A, Escuder-Gilabert L, Lopes NP, Villanueva-Camanas RM, Sagrado S, Medina-Hernandez MJ. Characterization of interactions between polyphenolic compounds and human serum proteins by capillary electrophoresis. Anal Bioanal Chem 2008; 391: 625-632

Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model[*]

Authors

Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model^[*]